01 How it works
MOTS-c activates AMPK, the cell’s energy sensor — the same switch exercise flips. In mice this improved insulin sensitivity, protected against diet-induced weight gain and boosted physical capacity. Natural levels rise with exercise and fall with age.
02 Common uses
03 Run profile
A gentle first week, a step up over the first month, then held. Three times a week, in the morning or before training, in twelve-week blocks.
The profile shows the shape. Ask for the numbers for your vial, your goal and your timeline.
04 Pairs well with
05 What to watch for
Injection-site irritation; some people report palpitations, trouble sleeping or mild stomach upset, and temporary fatigue or heavy legs in the first couple of weeks. Any palpitations, chest discomfort or irregular heartbeat — stop and get checked. Dose in the morning rather than late.
06 Evidence & status
Not approvedCompelling in animals; human research is at an early stage.
Not FDA-approved. Recommended 7–5 for the 503A compounding list by an FDA advisory panel in July 2026, a non-binding vote. On 28 October 2026 HHS issued an interim enforcement-discretion policy that lets state-licensed pharmacies and physicians compound single-ingredient MOTS-c (injected) while FDA rulemaking continues. It is still not on the 503A list, and there is no final FDA decision.
Sources
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistanceCell Metabolism, 2015 · Reference
- Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individualsJournal of Investigative Medicine, 2018 · Reference
- MOTS-c Functionally Prevents Metabolic DisordersMetabolites, 2023 · Review
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory CommitteeU.S. Food and Drug Administration, 2026 · Regulator document
- HHS Draft Policy Eases Enforcement on 6 Compounded PeptidesThe American Journal of Managed Care (AJMC), 2026 · Regulator document
- The Prohibited ListWorld Anti-Doping Agency, 2026 · Regulator document
Status and sources last checked November 3, 2026. Something out of date? Tell us.
07 How long until it works
There is no interventional human trial of MOTS-c, so there is no measured answer for people. The evidence is animal work: in the 2015 Cell Metabolism study, mice given MOTS-c for a week showed better insulin sensitivity, and over several weeks were protected from weight gain on a high-fat diet. The one human study on this page measured natural MOTS-c levels in blood and found they track with insulin sensitivity in lean people; it did not give anyone the peptide.
People using it report the first change as training capacity and energy over two to four weeks, often after a flat first week or two (see what to watch for). The run profile’s twelve-week block comes from common use, not from a trial.
08 MOTS-C vs NAD+
Both are sold for “cellular energy”, and both lack outcome trials in people, so the comparison is about mechanism and what each is for. MOTS-c acts on AMPK, the energy sensor exercise switches on, and its animal data are about metabolism: insulin sensitivity, fat gain, physical capacity. NAD+ is a coenzyme the body already makes, and the case for injecting it rests on topping up levels that fall with age; its oral precursors have human data on blood levels but little on outcomes.
If the goal is metabolic (training capacity, insulin sensitivity), MOTS-c is the one with animal evidence pointing that way. If it is general energy and healthy-ageing, NAD+ precursors by mouth have the most human data. Neither replaces the thing both mimic, which is exercise.
The NAD+ dossier →09 Stacking
NAD+ is the usual partner, and some people run MOTS-c alongside a GLP-1 medicine for metabolic support during weight loss. No study has tested either combination. The October 2026 HHS policy covers single-ingredient injected MOTS-c only.
10 Where it stands legally
MOTS-c is not approved by the FDA or any other regulator. In July 2026 the FDA’s advisory committee voted 7–5 to recommend it for the 503A compounding list, against FDA reviewers’ advice, and on 28 October 2026 HHS issued an interim policy under which it will not take enforcement action against licensed pharmacies and physicians compounding single-ingredient injected MOTS-c while rulemaking continues. That is a pause in enforcement, not an approval.
In sport, a substance with no regulatory approval falls under S0 of WADA’s Prohibited List, so MOTS-c is banned at all times for tested athletes.
11 FAQ
Does it replace exercise?
No. It is called an exercise mimetic because it flips one of the same switches, not because it replaces training.
Why mornings?
Some people find it energising enough to disturb sleep if taken late.
Is the early fatigue normal?
Many report heavy legs for the first week or two while adapting. If it persists, ask.
Has MOTS-c been tested in people?
Not as a treatment. The human study on this page measured natural MOTS-c levels in blood. The evidence that it does anything comes from mice.
Is MOTS-c banned in sport?
Yes, under WADA’s S0 category for non-approved substances, at all times.
Why morning or pre-training?
Because the animal data tie it to the same energy pathway exercise uses, and because evening doses are the ones people report sleep trouble with. Neither has been tested formally.
What are the palpitations about?
Some people report them in the first weeks. There is no human safety data to say how common or why. Stop and get checked rather than wait it out.
Educational information only — not medical advice. The Daily Stack does not sell or supply any products. Talk to a licensed healthcare professional about your own health decisions.